Gabapentin is usually given at a dose of 600 mg 3 times daily to patients with postherpetic neuralgia.
Gabapentin is FDA-approved for postherpetic neuralgia, and clinical trials show efficacy typically at a dosage of 600 mg 3 times daily. Gabapentin is safe for use in patients with cardiac disease, has a similar adverse effect frequency compared with tricyclic antidepressant agents, and is somewhat more expensive than the other agents used to treat postherpetic neuralgia.
